Hinge Health (NYSE:HNGE) is considered one of the most promising mid-cap healthcare stocks under $50, with positive outlooks from analysts. Citizens reaffirmed a Buy rating for HNGE with a target price of $65, citing strong ties with major players in the healthcare industry. HNGE employs AI to provide drug-free pain relief and has significant growth potential within the digital musculoskeletal market.

Read more at Yahoo Finance: Here is What Analysts Have to Say About Hinge Health (HNGE)